Results 161 to 170 of about 127,252 (263)

Theoretical Study on the Metabolic Mechanism of Heptachlor in Human Cytochrome P450 Enzymes. [PDF]

Int J Mol Sci
Zhao X, Zhang H, Shen X, Zheng Q, Wang S.   +4 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Soticlestat (TAK‐935) is a cholesterol 24‐hydroxylase inhibitor. A physiologically‐based pharmacokinetic model has been developed to predict potential soticlestat drug–drug interactions (DDIs) using the Simcyp v20 Population‐based Simulator and verified with data from single‐/multiple‐rising‐dose and clinical DDI studies.
Hongxia Jia, T. Eric Ballard, Liming Zhang, Lawrence Cohen, Mackenzie C. Bergagnini‐Kolev, Ian E. Templeton, Hannah M. Jones, Wei Yin   +7 more
wiley   +1 more source

Heterotropic Activation of Cytochrome P450 3A4 by Perillyl Alcohol. [PDF]

Pharmaceutics
Ryu JH, Yu J, Jeon JS, Jo S, Lee SM, Kim H, Park HJ, Oh SJ, Kim SK.   +8 more
europepmc   +1 more source

Computational Studies of Enzymes for C−F Bond Degradation and Functionalization

ChemPhysChem, EarlyView.
Enzyme‐mediated strategies for C−F bond cleavage offer a promising solution for addressing the environmental challenges posed by the Forever Chemicals. This review discusses how computational approaches – including molecular docking, molecular dynamics, QM/MM, and bioinformatics – enhance the understanding of enzymatic degradation mechanisms, guiding ...
Kendra M. Cunningham, Wook Shin, Zhongyue J. Yang   +2 more
wiley   +1 more source

Comparative study of cytochrome P450 expression in the kidneys of Lepus yarkandensis and Oryctolagus cuniculus. [PDF]

Sci Rep
Zhang J, Li Y, Shao D, Chao B, Liu G.
europepmc   +1 more source

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Conducting clinical studies on drug–drug‐gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically‐based pharmacokinetic (PBPK) modeling networks present a new avenue for exploring such complex scenarios, potentially informing ...
Simeon Rüdesheim, Helena Leonie Hanae Loer, Denise Feick, Fatima Zahra Marok, Laura Maria Fuhr, Dominik Selzer, Donato Teutonico, Annika R. P. Schneider, Juri Solodenko, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr   +14 more
wiley   +1 more source

Bacterial Cytochrome P450 Catalyzed Macrocyclization of Ribosomal Peptides. [PDF]

ACS Bio Med Chem Au
Liu J, Liu R, He BB, Lin X, Guo L, Wu G, Li YX.   +6 more
europepmc   +1 more source

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent.
Anna M. Becker, Mélusine Humbert‐Droz, Lorenz Mueller, Alen Jelušić, Avram Tolev, Isabelle Straumann, Isidora Avedisian, Livio Erne, Jan Thomann, Dino Luethi, Edna Grünblatt, Henriette Meyer zu Schwabedissen, Matthias E. Liechti   +12 more
wiley   +1 more source

Correction: Characterization of a cytochrome P450 that catalyzes the O-demethylation of lignin-derived benzoates. [PDF]

J Biol Chem
Wolf ME, Hinchen DJ, McGeehan JE, Eltis LD.   +3 more
europepmc   +1 more source

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

Clinical Pharmacology &Therapeutics, EarlyView.
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang, Logan Brooks, Denise M. Boudreau, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu   +6 more
wiley   +1 more source